David Jackson joins DxS
This article was originally published in Clinica
UK molecular diagnostics firm DxS has appointed David Jackson vice-president of business development and licensing. Dr Jackson will be based in the US and will be responsible for the company's companion diagnostics and technology licensing divisions. Dr Jackson previously worked for Response Genetics as executive vice-president, and before this was president and chief operating officer of CryoFluor Therapeutics, a company developing a novel cryosurgical platform. He also has "extensive consulting experience in personalised medicine", Manchester-based DxS said.